Levalbuterol in the treatment of patients with asthma and chronic obstructive lung disease

Journal of the American Osteopathic Association

Volumn 104, Issue 7, 2004, Pages 288-293

  D'Alonzo Jr , Gilbert E ^a,b,c  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

^c TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE; LEVALBUTEROL; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATATION; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; HUMANS; MOLECULAR STRUCTURE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 3242733880     PISSN: 00986151     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. National Institutes of Health. Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 97-4051, Bethesda, Md: National Institutes of Health; 1997.
2. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol. 2000;106:493-499.
3. American Academy of Allergy Asthma and Immunology. Pediatric Asthma: Promoting Best Practice: Guide for Managing Asthma in Children. Elk Grove Village, Ill: American Academy of Pediatrics 1999;1-157.
4. Mannino DM. COPD: Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121:121S-126S.
5. National Heart Lung and Blood Institute, US Department of Health and Human Services. Data Fact Sheet: Chronic Obstructive Pulmonary Disease (COPD). 2001;1-4.
6. National Institutes of Health, National Heart Lung and Blood Institute. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma. Revised 2002. NIH Publication: 02-3659. Bethesda, Md: National Institutes of Health; 2002.
7. Cherry DK, Burt CW, Woodwell DA. National ambulatory medical care survey: 2001 Summary. Adv Data. 2003;337:1-44.
8. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet. 1993; 342:833-837.
9. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA. 1994;271:1412-1416.
10. Pearlman DS, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992;327:1420-1425.
11. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med. 1996;335:841-847.
12. Suissa S, Ernst P, Boivin JF, Horwitz RI, Habbick B, Cockroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. Am J Respir Crit Care Med. 1994;149:604-610.
13. Baramki D, Koester J, Anderson AJ, Borish L. Modulation of T-cell function by (R)- and (S)-isomers of albuterol: anti-inflammatory influences of (R)-isomers are negated in the presence of the (S)-isomer. J Allergy Clin Immunol. 2002;109:449-454.
14. Hoshiko K, Morley J. Exacerbation of airway hyperreactivity by (±) salbutamol in sensitized guinea pig. Jpn J Pharmacol. 1993;63:159-163.
15. Cho SH, Hartleroad JY, Oh CK. (S)-albuterol increases the production of histamine and IL-4 in mast cells. Int Arch Allergy Immunol. 2001;124:478-484.
16. Perrin-Fayolle M. Salbutamol in the treatment of asthma. Lancet. 1995;346: 1101.
17. Xopenex (Levalbuterol HCI) Inhalation Solution. Physicians' Desk Reference. 57th ed. Montvale, NJ: Thomas PDR; 2003: 3115-3118.
18. Nelson HS, Bensch G, Pleskow WW, DiSantostefano R, DeGraw S, Reasner DS, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol. 1998;102:943-952.
19. Milgrom H, Skoner DP, Bensch G, Kim KT, Claus R, Baumgartner RA. Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol. J Allergy Clin Immunol. 2001;108: 938-945.
20. FDA's policy statement for the development of new stereoisomeric drugs. Chirality. 1992;4:338-340.
21. Penn RB, Frielle T, McCullough JR, Aberg G, Benovic JL. Comparison of R-, S-, and RS-albuterol interaction with human β1- and β2-adrenergic receptors. Clin Rev Allergy Immunol. 1996;14:37-45.
22. Templeton AG, Chapman ID, Chilvers ER, Morley J, Handley DA. Effects of S-salbutamol on human isolated bronchus. Pulm Pharmacol Ther. 1998;11:1-6.
23. Mitra S, Ugur M, Ugur O, Goodman HM, McCullough JR, Yamaguchi H. (S)-Albuterol increases intracellular free calcium by muscarinic receptor activation and a phospholipase C-dependent mechanism in airway smooth muscle. Mol Pharmacol. 1998;53:347-354.
24. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326:501-506.
25. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990;336: 1391-1396.
26. Dhand R, Goode M, Reid R, Fink JB, Fahey PJ, Tobin MJ. Preferential pulmonary retention of (S)-albuterol after inhalation of racemic albuterol. Am J Respir Crit Care Med. 1999;160:1136-1141.
27. Gumbhir-Shah K, Kellerman DJ, DeGraw S, Koch P, Jusko WJ. Pharmacokinetics and pharmacodynamics of cumulative single doses of inhaled salbutamol enantiomers in asthmatic subjects. Pulm Pharmacol Ther. 1999;12: 353-362.
28. Vaickus L, Schaefer K, Claus R. Impact of decreasing doses of racemic albuterol and levalbuterol on efficacy: A pooled analysis. J Allergy Clin Immunol. 2002;109:S233.
29. Milgrom H, Skoner D, Bensch G, Kim K, Claus R, Baumgartner RA. Letter to editor: reply to article written by Chowdhury: comparative efficacy of levalbuterol and racemic albuterol in the treatment of asthma. J Allergy Clin Immunol. 2002;110:325.
30. Asmus MJ, Hendeles L. Levalbuterol nebulizer solution: is it worth five times the cost of albuterol? Pharmacotherapy. 2000;20:123-129.
31. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr. 2003; 143(6):731-736.
32. Schreck DM, Brotea C, Shah SP. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma. Ann Emerg Med. 2001;38:S10.
33. Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest. 2003;123:128-135.